Rhythm Pharmaceuticals (RYTM) reported a Q1 net loss Wednesday of $0.81 per diluted share, narrowing from a loss of $2.35 a year earlier.

Four analysts polled by FactSet expected a loss of $0.73.

Revenue for the quarter ended March 31 was $32.7 million, up from $26.0 million a year earlier.

Analysts surveyed by FactSet expected $40.2 million.

The company said it expects its cash, cash equivalents and short-term investments of $314.5 million as of March 31 'will be sufficient to fund its operating expenses and capital expenditure requirements into 2027.'